A Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Avalglucosidase Alfa in Chinese Participants With Infantile-onset Pompe Disease (IOPD)
Latest Information Update: 04 Nov 2024
Price :
$35 *
At a glance
- Drugs Avalglucosidase alfa (Primary)
- Indications Glycogen storage disease type II
- Focus Adverse reactions
- Sponsors Genzyme-Corporation-Medtronic-(JV)
- 04 Nov 2024 New trial record